title: Second induction in pediatric patients with recurrent acute lymphoid leukemia using DFCI-ALL protocols.
abstract: Between 15% and 30% of children with acute lymphoblastic leukemia (ALL) experience disease recurrence. With the possible exception of patients presenting with late isolated extramedullary relapse, induction of second complete remission (CR) is employed as a stepping stone to allogeneic hematopoietic stem cell transplantation (HSCT). The authors report their institutional experience in the management of children with recurrent ALL using the Dana Farber Cancer Institute (DFCI) ALL protocol in patients treated initially with that same protocol. Successful reinduction was followed by allogeneic HSCT when possible. Between April 1986 and May 2003, 34 patients with recurrent ALL, treated at initial diagnosis with DFCI-ALL protocol therapy, were given the same protocol as repeat induction chemotherapy. The median age was 4.6 years at diagnosis and 7.1 years at recurrence. Median duration of CR1 was 30.3 months. Second CR was obtained in 29 (85%) patients. Twenty went on to allogeneic HSCT; 10 of them currently remain in CR. Two additional patients treated with chemotherapy without HSCT are also in continuous CR2. Overall, 13 (38%) of the 34 patients are alive with a median follow-up of 105 months. There were no toxic deaths due to the reinduction therapy. One child died of cardiac failure after autologous HSCT. The treatment of children with recurrent ALL using the DFCI-ALL protocol induction regimen after initial use of the same protocol is associated with a high rate of second CR with no excess toxicity. However, the overall prognosis in these patients remains unsatisfactory and needs to be improved.
authors.affiliation: Division of Hematology-Oncology, Hôpital Sainte Justine, Montréal, Quebec, Canada.
authors.forename: Jean-Hugues
authors.initials: JH
authors.lastname: Dalle
authors.forename: Albert
authors.initials: A
authors.lastname: Moghrabi
authors.forename: Pierre
authors.initials: P
authors.lastname: Rousseau
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Leclerc
authors.forename: Stephane
authors.initials: S
authors.lastname: Barrette
authors.forename: Mark L
authors.initials: ML
authors.lastname: Bernstein
authors.forename: Josette
authors.initials: J
authors.lastname: Champagne
authors.forename: Michele
authors.initials: M
authors.lastname: David
authors.forename: Jocelyn
authors.initials: J
authors.lastname: Demers
authors.forename: Michel
authors.initials: M
authors.lastname: Duval
authors.forename: Heather
authors.initials: H
authors.lastname: Hume
authors.forename: Patrick
authors.initials: P
authors.lastname: Meyer
authors.forename: Martin A
authors.initials: MA
authors.lastname: Champagne
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology*; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate